Chemotherapy of Breast Cancer: Can We Improve Outcome and Decrease Toxicity by Tailoring Therapy?

By Lidbrink E.   Bergh J.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 165-171

Adis International

Access to resources Recommend Favorite

Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?

By Diamond Jennifer R   Elias Anthony D  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 175-178

Future Medicine

Access to resources Recommend Favorite

Familial breast cancer in southern Finland - how prevalent are breast cancer families and can we trust the family history reported by patients?

By Eerola H.   Blomqvist C.   Pukkala E.   Pyrhonen S.   Nevanlinna H.  

European Journal of Cancer, Vol. 36, Iss. 9, 2000-06 ,pp. : 1143-1148

Elsevier

Access to resources Recommend Favorite

How can we improve the quality of reporting family history in colorectal cancer care? (And why does it matter?)

By Wilson Brenda J  

Colorectal Cancer, Vol. 2, Iss. 2, 2013-04 ,pp. : 99-102

Future Medicine

Access to resources Recommend Favorite

Lung cancer risk from radon in Ontario, Canada: how many lung cancers can we prevent?

By Peterson Emily   Aker Amira   Kim JinHee   Li Ye   Brand Kevin   Copes Ray  

Cancer Causes and Control, Vol. 24, Iss. 11, 2013-11 ,pp. : 2013-2020

Springer Publishing Company

Access to resources Recommend Favorite